NCNA - NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 | Benzinga
EDINBURGH, United Kingdom, Sept. 18, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced four presentations at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 being held October 11-15, 2023 in Boston, Massachusetts.
The details of NuCana's presentations at the meeting are as follows:
Abstract title: NUC-3373 in combination with irinotecan (NUFIRI) or oxaliplatin (NUFOX) and bevacizumab for second-line treatment of patients with advanced colorectal cancer (NuTide:302)
Poster number: B048
Session: Poster Session B
Session date and time: Friday, October 13 from 12:30pm-4:00pm
Presenting Author: Dr. Khurum Khan
Abstract title: Phase II study of NUC-3373, leucovorin, irinotecan (NUFIRI) + bevacizumab vs FOLFIRI + bevacizumab for the second-line treatment of patients with advanced/metastatic colorectal cancer (NuTide:323)
Poster number: B049
Session: Poster Session B
Date and time: Friday, October 13 from 12:30pm-4:00pm
Presenting Author: Professor Richard Wilson
Abstract title: Phase Ib/II open label, multi-arm, parallel cohort dose finding and expansion study of NUC-3373 in combination with pembrolizumab in patients with advanced solid tumors or docetaxel in patients with lung cancer (NuTide:303)
Poster number: C029
Session: Poster Session C
Session date and time: Saturday, October 14 from 12:30pm-4:00pm
Presenting Author: Professor Richard Wilson
Abstract title: NUC-7738 in combination with pembrolizumab in patients with metastatic melanoma: Phase 2 results from the NuTide:701 study
Poster number: C032
Session: Poster Session C
Session date and time: Saturday, October 14 from 12:30pm-4:00pm
Presenting Author: Professor Sarah Blagden
About NuCana
NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most ...